Table 2:

Current Clinical Trials of EZH2 inhibitors in lymphoma

Agent	Study Name	NCT ID	Phase	Eligible Lymphoma Subtypes	Expected accrual	Status
Tazemetostat (EPZ-6438)	Open-Label, Multicenter, phase 1/2 Study of Tazemetostat as a Single Agent in Subjects with Advanced Solid Tumors or with B-cell Lymphomas and Tazemetostat in Combination with Prednisolone in Subjects with DLBCL		I/II	Phase I: B-cell NHL and solid tumors; Phase II: DLBCL, FL	420	Phase I closed, phase II ongoing
	Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations	Phase II sub protocol:	II	NHL and solid tumors	49	Recruiting
	Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemotherapy (Epi-RCHOP)		Ib-II	DLBCL	133	Recruiting
	A Safety and Pharmacology Study of Atezolizumab Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma		I	DLBCL, FL	92	Recruiting
	Tazemetostat in Treating Patients with Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas with Liver Dysfunction		I	B-cell NHL and solid tumors	48	Anticipated start date: 3/16/2018
CPI-1205	A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas		I	B-cell NHL	41	Recruiting
GSK2816126	A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin’s Lymphomas, Solid Tumors and Multiple Myeloma		I	NHL, MM Expansion cohort: DLBCL	41	Closed to enrollment

Abbreviations: Diffuse Large B -cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Non-Hodgkin’s lymphomas (NHL); Multiple myeloma (MM)